Twist Bioscience Corp. — Blitz Index 56 (C)

Twist Bioscience scores 56 — a silicon DNA-synthesis platform whose creative destruction (C 12/15) leads, while GAAP profit still lags margin gains.

Last re-scored: October 25, 2026.

Score breakdown

Think we scored it wrong? Score it yourself →

Radar axes (0–100): Moat 56.7 · Speed 68 · Creative 80.

Watch item

Gates: G1 ✓ (confirmed) · G2 ✓ (estimate — bar ≈ $4.32B vs DNA-synthesis TAM alone ~3.1× the bar). 9 points below the threshold — first score.

Strengths

• 14 straight quarters of sequential growth through Q3 FY2026, with FY2026 guidance raised to $456–457M
• Gross margin improved monotonically 36.6% → 42.6% → 50.7% → 52.8% — unit synthesis costs collapsing
• Biopharma revenue +49% and genes shipped +56% in Q3 FY2026, with ~2,650 customers
• $300M upsized offering (Aug 2026) funds the push to adjusted EBITDA breakeven in Q4 FY2026
• No borrowings and a single share class — a clean capital and governance structure

Concerns

• Still GAAP-loss-making (FY2025 operating loss −$136.3M); margin gains have not yet become profit
• FY2025 net-loss improvement included a $48.8M gain on a business sale — the underlying loss persists
• SBC of $64.5M is 17.1% of FY2025 revenue — dilution is the largest single cost
• Enzymatic-synthesis entrants plus IDT and GenScript contest the platform's edge
• DNA-synthesis biosecurity screening and export controls, plus a large-customer concentration risk

Research notes

Thesis: a platform company at a threshold

Twist Bioscience scores 56 out of 100 under the BlitzLab v1.0 model, grade C, nine points below the 65-point threshold. That single sentence contains the whole tension of the company as of the scoring date, 25 October 2026. Twist passes both gates of the model — it has demonstrated product-market fit and durable growth, and the market it serves is large enough, on the model's test, to support a company ten times its current size — yet it has not converted growth into profit. Its strongest axis is creative destruction, at 12 out of 15, while its moat, at 34 out of 60, is the axis that most limits the score. Speed sits in between at 17 out of 25, and deductions of minus 7 pull the total back without triggering a FLAG, which requires deductions of 15 or more.

The item scores, stated exactly as scored, are: Speed — A1 growth 7 out of 10, A2 capital velocity 3 out of 5, A3 hiring and productivity 3 out of 5, A4 share velocity 4 out of 5, for a Speed total of 17 out of 25. Moat — B1 network effects 7 out of 18, B2 distribution scalability 9 out of 18, B3 market size 9 out of 12, B4 gross margin 9 out of 12, for a Moat total of 34 out of 60. Creative destruction — C1 order replaced 4 out of 5, C2 irreversible behaviour change 4 out of 5, C3 cost-structure change 4 out of 5, for a total of 12 out of 15. Deductions — D1 debt negative 2 out of minus 10, D2 revenue quality negative 3 out of minus 10, D3 governance 0 out of minus 5, D4 regulatory and social cost negative 2 out of minus 5, for a deductions total of minus 7. The arithmetic is 17 plus 34 plus 12 minus 7, which equals 56.

In the model's own language, Twist is a company at a threshold: in the acceleration phase of blitzscaling, but before harvest. The evidence for acceleration is unusually broad-based, spanning revenue, customer counts, shipped volume, segment growth, and margin. The evidence for harvest is missing. That asymmetry — strong operating signals on one side, an unclosed profitability gap on the other — is what the rest of this research body examines, item by item, with every figure grounded in the company's filings and, where the score file says so, in press reporting.

Twist Bioscience, founded in 2013 and listed in October 2018, sells synthetic DNA made on a silicon-based platform. Its customers use that DNA in biopharmaceutical research, next-generation sequencing (NGS), and related life-science work. The company is classified in this scoring as GROWTH, because its trailing-twelve-month revenue of $431.8 million is below $1 billion. This is a first scoring for Twist under the model; there is no blind-test history to compare against, and the scoring rests heavily on direct review of the company's filings on SEC EDGAR — the fiscal 2025 Form 10-K and the fiscal 2026 second- and third-quarter Forms 10-Q — supplemented, for market size and share price, by press-reported material, which the score file labels accordingly.

Speed: growth is real, sustained, and still loss-making

Growth is the most straightforward part of the Twist story, and the score reflects both its strength and its limit. Revenue rose from $245.1 million in fiscal 2023 to $313.0 million in fiscal 2024, an increase of 27.7 percent, and then to $376.6 million in fiscal 2025, an increase of 20.3 percent. Trailing-twelve-month revenue at the scoring date stood at $431.8 million. Third-quarter fiscal 2026 revenue grew 23.2 percent year on year, and the company raised its fiscal 2026 guidance to $456–457 million. The growth rate has decelerated from 27.7 percent to 20.3 percent on the annual figures, which is part of why A1 growth scores 7 rather than higher, but the absolute level of growth remains high, and the direction of acceleration is maintained into the third quarter. What keeps A1 below 8, in the score file's reasoning, is the absence of profitability: growth without profit cannot earn the top band of this item.

The more distinctive growth fact is duration. Twist reported fourteen consecutive quarters of quarter-on-quarter growth through the third quarter of fiscal 2026. A single strong quarter can be an accident of timing; fourteen in a row is a pattern, and it is one of the three pillars on which the G1 gate verdict rests. The other two are organic growth and order-book-like demand, and the volume and customer figures below supply the texture for both. The gate does not depend on a second growth curve. The score file identifies a candidate second curve — synthetic DNA for artificial-intelligence drug-discovery workflows — but notes explicitly that the G1 pass does not rely on it. The first curve is still alive on its own evidence.

Capital velocity, A2 at 3 out of 5, tells a more qualified story. Cash and short-term investments fell from $232.4 million at 30 September 2025 to $166.8 million at 30 June 2026, before any new financing. On 4 August 2026, the company completed a $300 million upsized offering, which replenished the balance sheet. The score file treats this symmetrically: dependence on an equity raise rather than self-generated funding is what prevents a score of 4 or above, while the success of the raise itself — the demonstrated ability to access capital at scale — is what prevents a score as low as 2. The company therefore enters the final quarter of fiscal 2026 with funding in hand, but the funding came from shareholders, not from operations, and that distinction matters for everything that follows about profitability.

Hiring and productivity, A3 at 3 out of 5, is scored on a thinner evidence base, and the score file is candid about that. Headcount stood at 979 employees at 30 September 2025, as confirmed in the fiscal 2025 Form 10-K, split across research and development (91), sales, marketing and customer support (278), general and administrative (198), and operations and manufacturing (412). Revenue per employee improved from $0.385 million in fiscal 2025 to $0.441 million on a trailing-twelve-month basis. That improvement is real, but two limits keep the score at 3: only one year of employment data is confirmed in the filings reviewed, so the speed of any hiring blitz cannot be established with confidence, and the absolute level of revenue per employee remains low. A manufacturing-heavy workforce — operations and manufacturing is the largest single group, at 412 of 979 — is consistent with a company that makes a physical product at scale, but it also means productivity gains must come substantially from the factory and the platform, not from headcount leverage alone.

Share velocity, A4 at 4 out of 5, is where the breadth of demand shows most clearly. The customer count reached approximately 2,650, up about 7 percent year on year from approximately 2,480. Genes shipped reached approximately 369,000, compared with approximately 237,000 in the prior-year period, an increase of 56 percent. Biopharma revenue reached $40.4 million, up 49 percent. Both reported segments grew together: NGS revenue rose 12 percent, and DNA synthesis and protein revenue rose 39 percent. These are company-reported figures, and the score file labels them press-reported in its evidence table, so they should be read with that label attached. What prevents a full score of 5 is the absence of a disclosed market-share figure: the velocity of share gain can be inferred from multiple directions at once, but the share itself is not published, so the top mark is withheld.

Moat: a platform moat, not a network moat

If creative destruction is what Twist does to the world, moat is what protects Twist from the world doing the same thing back to it — and here the score is at its most discriminating. The Moat total of 34 out of 60 is the largest single drag on the overall score relative to its weight, and the composition of that total matters more than the total itself. The two strongest moat items, market size and gross margin, score 9 each. The two weakest, network effects and distribution scalability, score 7 and 9 respectively out of a much larger maximum of 18 each. The structure of the moat, in short, is a platform whose economics improve with scale, without the self-reinforcing user-to-user dynamics that the blitzscaling model rewards most highly.

B1 network effects, at 7 out of 18, is the lowest moat score relative to its maximum, and the reasoning is blunt: Twist has no genuine user-to-user network effect. Customers do not make the product more valuable for other customers merely by joining. What Twist does have is platform workflow embedding — a repeat-order customer base whose ordering habits, designs, and processes become intertwined with the Twist platform — together with silicon-synthesis patents and know-how. Those are real advantages, but they are not network effects in the strict sense, and they are contestable: customers can switch platforms, and named alternatives exist, including IDT and GenScript. The score file also notes that any contribution from data gravity — the idea that accumulated order and design data makes the platform progressively better — is not disclosed as a revenue contribution, so it cannot be credited beyond the embedding effect. A score of 7 therefore reflects a partial, workflow-based stickiness rather than a network moat, and the score file itself flags this as a candidate area for model refinement: platform companies whose stickiness comes from installation and repeat ordering may be systematically under-scored by a B1 anchor built around user-to-user networks.

B2 distribution scalability, at 9 out of 18, captures the other half of the platform argument. Twist sells directly through a global sales organisation, and the silicon platform's throughput expands as synthetic orders grow, so that unit costs fall as volume rises. Distribution, in this framing, is scalable because the factory and the platform scale together: more orders do not require a proportionally larger sales and manufacturing apparatus in the way a purely services-based model would. The limit is competition at the frontier of the technology itself. Enzymatic synthesis entrants, together with established competitors, contest the same distribution channels and the same customers, which caps the scalability score. Distribution can expand, but it expands into a contested market rather than an empty one.

B3 market size, at 9 out of 12, is the item that carries the G2 gate, and the gate logic deserves to be stated plainly because it is unusually robust to definitional argument. The model's test is that the addressable market over ten years must be at least ten times current revenue. Ten times trailing-twelve-month revenue of $431.8 million is approximately $4.32 billion. On the narrow definition — the DNA synthesis market alone — press-reported market research puts the market at $2.78 billion in 2024 rising to $13.6 billion by 2030, which is approximately 3.1 times the bar. On the broad definition — synthetic biology as a whole — the figures are $19.7 billion rising to $86.2 billion by 2030, approximately 20 times the bar. The narrow definition alone clears the bar comfortably, so the pass does not depend on choosing the flattering definition. That robustness is why the gate verdict is recorded as a pass on an estimated and press-reported basis rather than a borderline one. The score stops at 9 rather than higher for a different reason: Twist's current revenue is small relative to either market definition, and the broad synthetic-biology figure is wider than Twist's actual reachable market, so market size is large but demonstrated share of it is still small.

B4 gross margin, at 9 out of 12, is the financial proof that the platform's unit economics are moving in the right direction. Gross margin improved monotonically: 36.6 percent in fiscal 2023, 42.6 percent in fiscal 2024, 50.7 percent in fiscal 2025, and 52.8 percent in the third quarter of fiscal 2026. That progression is the score file's central piece of evidence for collapsing unit synthesis cost — the claim that making a gene on silicon gets cheaper, in margin terms, as the platform matures. The reason the score is 9 rather than higher is that margin improvement has not yet become operating profit: the fiscal 2025 operating loss was still negative $136.3 million. A rising gross margin that has not reached the bottom line is progress, not arrival, and the model scores it accordingly.

Creative destruction: the strongest axis

Creative destruction, at 12 out of 15, is the axis that carries Twist's score, and all three items score 4 out of 5 — high, but each withheld from the top mark for a specific, named reason. The pattern is consistent: the destruction is real and measurable, but it is incomplete, and in one case it is already being contested by a next generation of destroyers.

C1, the order being replaced, at 4 out of 5, is the clearest of the three. The order under attack is legacy chemical and column-based DNA synthesis, and the replacement is silicon-chip mass synthesis. This is a platform transition in the classic sense: it changes the speed, the scale, and the unit price at which synthesis happens, rather than merely improving an existing process at the margin. The reason the score is not 5 is that the replacement is not one-directional. Enzymatic synthesis, a next-generation approach, is approaching from behind Twist with the same logic Twist used against chemical synthesis — faster, cheaper, different chemistry. Twist is therefore both destroyer and potential destroyed, and the model records that symmetry by withholding the top mark.

C2, irreversible behaviour change, at 4 out of 5, asks whether customers have actually changed what they do, in a way that is hard to reverse. The measured evidence is the demand data already cited: biopharma revenue up 49 percent and genes shipped up 56 percent, together with the observation, reported by the company, that artificial-intelligence drug-discovery workflows are using synthetic DNA as a standard input. When a research workflow is built around ordering synthetic DNA as a routine consumable rather than synthesising it in-house or ordering it through a slower legacy route, reverting becomes costly in time and in process redesign. The limit, again, is stage: demand remains centred on research use, and the conversion of large NGS customers from research use to commercial assay use is still in progress, as discussed below. Behaviour has changed in the laboratory; its commercial completion is pending, so 5 is withheld.

C3, cost-structure change, at 4 out of 5, is the mirror image of the gross-margin story in B4, read from the customer's side rather than Twist's. The margin progression from 36.6 percent to 52.8 percent is, in the score file's reasoning, itself the financial evidence that the cost structure of gene synthesis for customers is falling: a supplier whose own unit costs collapse can pass lower costs through, or capture them as margin, and either way the customer's cost of obtaining a synthetic gene is structurally lower than under the legacy order. The qualification is identical to B4's: Twist itself is not yet profitable on a GAAP basis, so this is a cost collapse in progress rather than a completed one. The model scores a transition, not a destination.

Taken together, the three C items describe a coherent creative-destruction thesis: a new production method, adopted as a standard input in new workflows, at a falling unit cost. That thesis is the strongest part of the Twist case, and it is why a company with a 56 total still reads as strategically interesting rather than merely mediocre. The question the rest of the score raises is whether that thesis can be defended and monetised before the next destroyer arrives.

Deductions and risks: clean capital structure, unclean earnings quality

Deductions total minus 7, well short of the FLAG threshold, but their composition is instructive because it separates what is clean about Twist from what is not. The clean parts are the capital structure and the governance. The unclean parts are earnings quality and a specific set of external risks.

D1 debt, at negative 2 out of minus 10, is almost a non-story on leverage and a story on dilution. Twist carries no borrowings, and cash and short-term investments stood at $166.8 million before the August 2026 raise, so leverage concern on its own would score zero. The entire deduction comes from stock-based compensation: $64.5 million in fiscal 2025, equal to 17.1 percent of revenue. That is, in the score file's words, the single largest dilution cost, and it is large enough to warrant a deduction even in the absence of debt. Shareholders are not exposed to creditors, but they are exposed to steady dilution through equity pay, and the model records that cost explicitly rather than treating a debt-free balance sheet as cost-free.

D2 revenue quality, at negative 3 out of minus 10, is the most consequential deduction for reading the headline loss figures. The fiscal 2025 net loss of negative $77.7 million improved relative to the prior year, but that improvement included a $48.8 million gain from a business divestiture. Strip out a disclosed non-recurring gain of that size, and the underlying loss-making structure is worse than the headline improvement suggests. Fiscal 2025 operating cash flow was negative $47.6 million, which corroborates the picture of a company still consuming cash from operations on an annual basis. Against that, the third quarter of fiscal 2026 produced operating cash flow of positive $1.12 million on a press-reported basis — the first positive signal of its kind in the record reviewed. The score file treats that single quarter carefully: it is why the deduction is negative 3 rather than negative 4, but one quarter cannot establish a structural turn, and the score does not pretend otherwise. The score file also flags this area as a model-refinement candidate, since the current D2 bands do not distinguish finely enough between a disclosed non-recurring gain and a concealment of underlying losses.

D3 governance, at 0 out of minus 5, is clean. Twist has a single class of common stock, confirmed against the balance sheet in the fiscal 2025 Form 10-K, with no Class B shares identified and therefore no dual-class voting trigger. Whatever else is uncertain about Twist, control is not entrenched through a separate voting class, and the model deducts nothing here.

D4 regulatory and social cost, at negative 2 out of minus 5, records two exposures that are inherent to the business rather than the product of misconduct. The first is biosecurity screening and export controls on DNA synthesis, identified as a risk factor in the fiscal 2025 Form 10-K: a company that synthesises DNA at scale operates under screening obligations and export restrictions that can constrain what it sells and to whom, and those obligations can tighten. The second is customer concentration in transition: one large NGS customer is moving a research assay toward commercial use, an event mentioned on the first-quarter fiscal 2026 call on a press-reported basis. That transition is simultaneously an opportunity and a concentration risk, because a single customer's commercial decision can move a meaningful part of revenue. No large ongoing sanctions or litigation matters are identified in the record reviewed, which is why the deduction stops at negative 2.

Beyond the scored deductions, the risk section of the score file names the competitive threat plainly: enzymatic-synthesis entrants plus established competitors such as IDT and GenScript contest the durability of the platform advantage. That is not a scored item on its own, but it is the thread that connects B1, B2, and C1 — the moat is contestable, the distribution is contested, and the destruction is itself subject to destruction.

Blitzscaling fit: acceleration without harvest

The blitzscaling reading of Twist, as set out in the score file, is that its primary growth lever is platform — the generational replacement of the technology stack itself, from chemical and column synthesis to silicon synthesis. Its secondary lever is data: accumulated synthetic-DNA order data should, in principle, make design and optimisation progressively stronger, but since that data contribution is not separately disclosed as revenue, it remains a secondary lever rather than a primary one. Network effects, distribution, and capital are the weak levers: no user-to-user network, direct distribution that is expanding but contested, and capital that depends on equity raises.

The speed-versus-efficiency trade-off, in this reading, is being managed in an unusual way. Twist is achieving revenue growth and margin improvement at the same time — 20.3 percent growth in fiscal 2025 alongside a 50.7 percent gross margin, and 23.2 percent growth in the third quarter of fiscal 2026 alongside a 52.8 percent margin. That combination is the classic blitzscaling pattern of maintaining speed while improving unit economics. What makes Twist atypical is that the improvement has not yet reached profitability, so the speed is still funded externally. The $300 million raise is the fuel for the next phase, but fuel bought from shareholders is not the same as fuel generated by the business, and the distinction is the central unresolved question of the score.

That is why the score file's verdict on stage is "a company at the threshold." Fourteen quarters of growth, improving margins, and fresh capital satisfy the conditions for acceleration. The first test of harvest, in the score file's framing, is the re-confirmation of adjusted EBITDA breakeven in the fourth quarter of fiscal 2026. That quarter's results are post-scoring-date and are therefore excluded from this scoring, and the company's own announcement date for the quarter had not been published as of the scoring date; a date in mid-November 2026 circulates only as an estimate. This research body therefore records that quarter as a future marker — a reporting event to observe — without anticipating its outcome in either direction. The score file's own formulation of the risk is worth preserving verbatim in substance: if margin improvement does not become profit, Twist remains a high-growth, loss-making platform funded by raises, and the blitzscaling premise that speed creates a moat will not yet have been demonstrated in cash terms.

What to watch

The watch list follows directly from the scored items, and each entry is framed as a question to be answered by a future filing or company announcement, not as a prediction.

First, the fourth-quarter fiscal 2026 results, when the company announces them, will show whether the third quarter's positive operating cash flow of $1.12 million, press-reported, was the start of a pattern or a single-quarter event, and whether adjusted EBITDA breakeven is re-confirmed. The annual operating cash flow figure, negative $47.6 million in fiscal 2025, is the baseline against which any change should be measured, and the treatment of any further non-recurring gains should be examined with the same care applied to the $48.8 million divestiture gain in fiscal 2025.

Second, the customer and volume series should be tracked on the same bases as this scoring: customer count around 2,650, genes shipped around 369,000, biopharma revenue at $40.4 million in the quarter, and the two segment growth rates — NGS at 12 percent and DNA synthesis and protein at 39 percent. A break in the fourteen-quarter sequence of quarter-on-quarter growth would matter more than any single quarter's growth rate, because duration is what the G1 verdict rests on.

Third, the gross-margin series — 36.6 percent, 42.6 percent, 50.7 percent, 52.8 percent — should be tracked for continuation or plateau, together with the operating loss, negative $136.3 million in fiscal 2025. Margin without operating leverage is the central tension of the score, and the two series must be read together.

Fourth, the large NGS customer's research-to-commercial transition, and any disclosure about biosecurity screening or export controls, should be watched as the concrete form of the D4 risks. These are the exposures that could move revenue or constrain sales independently of demand for synthesis itself.

Fifth, stock-based compensation, at $64.5 million or 17.1 percent of revenue in fiscal 2025, should be tracked as the persistent cost of the current capital structure. A debt-free balance sheet is a genuine strength; it is not a dilution-free one.

Finally, the competitive question — whether enzymatic synthesis entrants and established competitors such as IDT and GenScript narrow the platform advantage — should be watched through the same lenses the score uses: customer retention and switching, segment growth rates, and margin. If the moat items weaken while creative destruction stays strong, the score file's structural diagnosis will have been confirmed: a company that can destroy an old order faster than it can defend the new one.

Score summary

Twist Bioscience scores 56 out of 100, grade C, under BlitzLab v1.0 as of 25 October 2026: Speed 17 out of 25 (A1 7, A2 3, A3 3, A4 4), Moat 34 out of 60 (B1 7, B2 9, B3 9, B4 9), Creative Destruction 12 out of 15 (C1 4, C2 4, C3 4), Deductions minus 7 (D1 negative 2, D2 negative 3, D3 0, D4 negative 2). Both gates pass. No FLAG applies. The score sits nine points below the 65-point threshold. The research case, in one line, is that creative destruction is proven, growth is sustained, the platform moat is real but contestable, and profitability is the unclosed gap between acceleration and harvest.

More Frontier companies

Other Frontier names on the Blitz Index, highest score first: Rocket Lab (62/B), Tesla (62/B), Illumina, Inc. (61/B).

Next earnings

Nov 12, 2026 · Before open · Confirmed

Coverage

Twist Bioscience Corp. · Q4 FY2026 due Nov 12, 2026 (BMO, confirmed) · Score 56 · Grade C

Embed this score

Copy the HTML below to show this score on your site. The badge links back to this page and updates automatically when the score changes.

<a href="https://blitzlab.app/companies/twst/"><img src="https://blitzlab.app/badge/twst.svg" alt="Twist Bioscience Corp. Blitz Index 56/C — BlitzLab"></a> Copy HTML

Preview:

BlitzLab scores businesses against a scholar’s standard — not investment advice. No price targets, no buy/sell recommendations. Figures are from SEC filings (XBRL) as labeled in the source scorecard.